Sign In
Buy DMTK
$0.0940
+0 (+0%)
At Close: Oct 21, 2024
DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that SKIN, the official journal of the National Society
DermTech, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
08:01pm, Tuesday, 10'th Mar 2020
DermTech, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Daily Insider Ratings Round Up 3/3/20
01:09pm, Saturday, 07'th Mar 2020
Tables of the top insider purchases and sales filed with the SEC on 3/3/20, based on dollar value. Dollar values often do not equate with significance when it c
Cowen’s Zach Fisher at 2nd SPAC Roundtable: High Quality Participants Give SPACs Validation
04:33pm, Thursday, 05'th Mar 2020
Zach Fisher, Managing Director, TMT Investment Banking Special purpose acquisition companies, or SPACs, now account for approximately one fourth of the entire U.S. IPO market, a result of higher-quali
Large Registry Study Demonstrates Clinicians Use DermTech’s Non-Invasive Gene Expression Testing to Improve Early Melanoma Detection
01:00pm, Thursday, 05'th Mar 2020
DermTech, Inc. (NASDAQ:DMTK) announced the Journal of Drugs and Dermatology has published the results of a large registry study.
DermTech to Participate at the 2020 BTIG Healthcare Conference
09:05pm, Tuesday, 03'rd Mar 2020
DermTech to Participate at the 2020 BTIG Healthcare Conference
DermTech Announces $65 Million Private Placement
11:00am, Monday, 02'nd Mar 2020
DermTech Announces $65 Million Private Placement
Cowen’s Chris Weekes at 2nd SPAC Roundtable: SPACs Now Part of Conversation with Most Companies Seeking Public Listing
08:57pm, Wednesday, 26'th Feb 2020
Chris Weekes, Managing Director, Capital Markets Much of the recent success of special purpose acquisition companies, or SPACs, is due to a watershed structural change: the separation of the vote and
Financial Survey: RadNet (NASDAQ:RDNT) & DermTech (NASDAQ:DMTK)
08:50am, Saturday, 22'nd Feb 2020
RadNet (NASDAQ:RDNT) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitabilit
DermTech to Present at Upcoming Investor Conferences
10:29pm, Tuesday, 11'th Feb 2020
DermTech to Present at Upcoming Investor Conferences
Cowen’s Tim Manning at 2nd SPAC Roundtable: Fundamental Investor Interest in SPACs On Rise
08:06pm, Monday, 10'th Feb 2020
Tim Manning, Managing Director, Special Situations at Cowen Inc. Cowen Inc. is far and away the leader in secondary-market trading of SPAC shares, giving it a unique window into the so-called de-SPAC
Head-To-Head Review: Veracyte (NASDAQ:VCYT) vs. DermTech (NASDAQ:DMTK)
07:04am, Sunday, 19'th Jan 2020
Veracyte (NASDAQ:VCYT) and DermTech (NASDAQ:DMTK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst r
DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay
10:45pm, Thursday, 16'th Jan 2020
DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay
CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTech’s Pigmented Lesion Assay (PLA)
01:00pm, Wednesday, 08'th Jan 2020
CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTech’s Pigmented Lesion Assay (PLA)
DermTech’s Pigmented Lesion Assay (PLA) Receives Medicare Coverage
01:00pm, Thursday, 02'nd Jan 2020
DermTech’s Pigmented Lesion Assay (PLA) Receives Medicare Coverage
